Form 4: BIO-KEY CTO Plans Acquisition of 25,000 Restricted Shares

BIO-KEY International's Chief Technology Officer, Mira K. Lacous, has reported a planned acquisition of 25,000 restricted common shares under a Rule 10b5-1(c) plan.

Summary

• Mira K. Lacous, Chief Technology Officer of BIO-KEY INTERNATIONAL INC (BKYI), has reported a planned acquisition of 25,000 shares of common stock.
• The transaction is scheduled to occur on September 2, 2025, with a transaction price of $0 per share, indicating a grant.
• These are Restricted Stock Units (RSUs) granted under the Issuer's 2023 Stock Incentive Plan, as amended.
• The shares will vest in three equal annual installments on each of the next three anniversaries of the grant date, contingent on continued employment or service to the Issuer.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this planned transaction, Mira K. Lacous will beneficially own 35,758 shares of common stock.
• This total does not include options to purchase an additional 87 shares.

Sentiment

Score: 7

Explanation: The planned grant of restricted stock to a key executive is generally positive as it aligns interests and incentivizes retention, but it's a routine compensation event rather than a significant operational or financial breakthrough.

Positives

• The grant of restricted stock aligns management incentives with long-term shareholder value, as vesting is tied to continued employment and future performance.
• Indicates continued commitment of a key executive (CTO) to the company's long-term strategy and success.
• Utilizes the company's 2023 Stock Incentive Plan, a standard mechanism for executive compensation and retention.

Negatives

• No immediate cash inflow for the executive from this grant, as it's restricted stock with a future vesting schedule.
• Potential for minor dilution if the shares are newly issued, though the Form 4 does not specify the source of the shares.

Risks

• The vesting of the restricted shares is subject to the Chief Technology Officer's continued employment or service; unvested shares would be forfeited if employment ceases.
• The ultimate value of the granted shares to the executive and the company's cost will depend on the future market price of BIO-KEY International's common stock.

Future Outlook

The restricted stock grant, scheduled for September 2, 2025, will vest in three equal annual installments on the anniversaries of that grant date, subject to the Chief Technology Officer's continued employment, indicating a long-term incentive structure and commitment.

Industry Context

Grants of restricted stock to key executives are a common practice in the technology sector to align executive incentives with long-term company performance and ensure retention. This is a standard component of executive compensation packages, often structured under Rule 10b5-1 plans for pre-planned transactions.

Stakeholder Impact

• Shareholders: Potential for minor dilution from new share issuance (if applicable), but also improved alignment of executive incentives with long-term shareholder value.
• Employees: Reinforces the company's commitment to executive retention and performance-based compensation, particularly for key personnel.

Next Steps

• The restricted shares will vest in three equal annual installments on the anniversaries of the planned September 2, 2025 grant date, contingent on continued employment.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned restricted stock grant to a key executive, which is a standard compensation practice. While it aligns executive incentives with long-term performance, it does not present new material information that would significantly alter the investment thesis for BIO-KEY International. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific transaction.

Keywords

BIO-KEY International, BKYI, Mira K Lacous, Chief Technology Officer, CTO, Restricted Stock, Stock Grant, Executive Compensation, SEC Form 4, Insider Transaction, Stock Incentive Plan, Rule 10b5-1